Pub Date : 2012-04-01DOI: 10.1097/01.NEP.0000414765.89291.D3
M. Coleman
{"title":"AKI Risk Factors Up, but Incidence Down in AMI Patients","authors":"M. Coleman","doi":"10.1097/01.NEP.0000414765.89291.D3","DOIUrl":"https://doi.org/10.1097/01.NEP.0000414765.89291.D3","url":null,"abstract":"","PeriodicalId":380758,"journal":{"name":"Nephrology Times","volume":"6 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2012-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114177953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2012-04-01DOI: 10.1097/01.NEP.0000414763.04540.27
M. Hogan
In recipients of a living-related donor kidney, induction therapy with autologous mesenchymal stem cells (MSCs) led to a lower rate of acute rejection and quicker recovery of renal function compared with anti-interleukin (IL)-2 receptor antibody, but the results are preliminary, experts interviewed for this article cautioned. The fi ndings were published in the Journal of the American Medical Association (2012;307:1169-1177). “This is the fi rst time such a study like this has been done,” said Jonathan Bromberg, MD, PhD, Chief of the Division of Transplantation and Professor of Surgery and of Microbiology and Immunology at the University of Maryland, when asked to comment on the fi ndings in a phone interview.
{"title":"Stem Cell Induction Successful in Small Trial of Living-Related Kidney Transplants","authors":"M. Hogan","doi":"10.1097/01.NEP.0000414763.04540.27","DOIUrl":"https://doi.org/10.1097/01.NEP.0000414763.04540.27","url":null,"abstract":"In recipients of a living-related donor kidney, induction therapy with autologous mesenchymal stem cells (MSCs) led to a lower rate of acute rejection and quicker recovery of renal function compared with anti-interleukin (IL)-2 receptor antibody, but the results are preliminary, experts interviewed for this article cautioned. The fi ndings were published in the Journal of the American Medical Association (2012;307:1169-1177). “This is the fi rst time such a study like this has been done,” said Jonathan Bromberg, MD, PhD, Chief of the Division of Transplantation and Professor of Surgery and of Microbiology and Immunology at the University of Maryland, when asked to comment on the fi ndings in a phone interview.","PeriodicalId":380758,"journal":{"name":"Nephrology Times","volume":"56 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2012-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127957695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2012-04-01DOI: 10.1097/01.NEP.0000414759.81668.40
M. Hogan
There’s a new player in anemia management for patients on dialysis— once-monthly peginesatide, which was approved by the Food and Drug Administration (FDA) on March 27. “In the United States where only epoetin alfa, as Epogen, and darbepoetin are available in the dialysis market, this represents a novel agent to compete with the existing agents in the marketplace,” said Nephrology Times Editorial Board Chair Ajay K. Singh, MBBS, MBA, in a phone interview. “It’s a major milestone.” Dr. Singh is Director of Global Programs and Associate Professor of Medicine at Harvard Medical School, as well as a physician in the Division of Renal Medicine and Director of Postgraduate Medical Education in the Department of Medicine at Brigham and Women’s Hospital. Peginesatide is given less frequently than epoetin alfa, which typically is administered one to three times a week. “The advantage is clearly the oncemonthly administration, putting a lot of convenience to the management of anemia,” said Brigitte Schiller, MD, Chief Medical Offi cer of Satellite Healthcare and a member of the Scientifi c Advisory Board of Affymax, which discovered peginesatide and is co-commercializing it in the United States with Takeda, under the brand name Omontys. “I would think of it as a simplifying anemia management approach for the nurses, the providers, and for patients,” Dr. Schiller said in a phone interview. Peginesatide Approval Introduces Competition into Antianemia Drug Market
3月27日，美国食品和药物管理局(FDA)批准了一种新的透析患者贫血治疗药物——每月一次的佩吉奈塞肽。《肾脏病时报》编辑委员会主席Ajay K. Singh, MBBS, MBA在电话采访中说:“在美国，透析市场上只有eppoetin，如Epogen和darbepoetin，这代表了一种新的药物，可以与市场上现有的药物竞争。”“这是一个重要的里程碑。”Singh博士是哈佛医学院全球项目主任和医学副教授，也是Brigham and Women 's Hospital医学部肾医学部医生和研究生医学教育主任。Peginesatide的使用频率低于epoetin，后者通常每周使用一到三次。卫星医疗首席医疗官、Affymax科学顾问委员会成员Brigitte Schiller医学博士说:“优势显然是每月给药一次，为贫血的管理提供了很多便利。”Affymax发现了peginesatide，并与武田在美国合作将其商业化，以Omontys的品牌命名。席勒博士在电话采访中说:“我认为这对护士、提供者和患者来说是一种简化贫血管理的方法。”pegineside的批准为抗贫血药物市场带来了竞争
{"title":"Peginesatide Approval Introduces Competition into Antianemia Drug Market","authors":"M. Hogan","doi":"10.1097/01.NEP.0000414759.81668.40","DOIUrl":"https://doi.org/10.1097/01.NEP.0000414759.81668.40","url":null,"abstract":"There’s a new player in anemia management for patients on dialysis— once-monthly peginesatide, which was approved by the Food and Drug Administration (FDA) on March 27. “In the United States where only epoetin alfa, as Epogen, and darbepoetin are available in the dialysis market, this represents a novel agent to compete with the existing agents in the marketplace,” said Nephrology Times Editorial Board Chair Ajay K. Singh, MBBS, MBA, in a phone interview. “It’s a major milestone.” Dr. Singh is Director of Global Programs and Associate Professor of Medicine at Harvard Medical School, as well as a physician in the Division of Renal Medicine and Director of Postgraduate Medical Education in the Department of Medicine at Brigham and Women’s Hospital. Peginesatide is given less frequently than epoetin alfa, which typically is administered one to three times a week. “The advantage is clearly the oncemonthly administration, putting a lot of convenience to the management of anemia,” said Brigitte Schiller, MD, Chief Medical Offi cer of Satellite Healthcare and a member of the Scientifi c Advisory Board of Affymax, which discovered peginesatide and is co-commercializing it in the United States with Takeda, under the brand name Omontys. “I would think of it as a simplifying anemia management approach for the nurses, the providers, and for patients,” Dr. Schiller said in a phone interview. Peginesatide Approval Introduces Competition into Antianemia Drug Market","PeriodicalId":380758,"journal":{"name":"Nephrology Times","volume":"47 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2012-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115782815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2012-04-01DOI: 10.1097/01.NEP.0000414760.58797.73
M. Hogan
{"title":"Integrated Nephrology Care Model Gains Traction","authors":"M. Hogan","doi":"10.1097/01.NEP.0000414760.58797.73","DOIUrl":"https://doi.org/10.1097/01.NEP.0000414760.58797.73","url":null,"abstract":"","PeriodicalId":380758,"journal":{"name":"Nephrology Times","volume":"14 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2012-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121587529","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2012-03-01DOI: 10.1097/01.NEP.0000413832.96692.2A
F. Lowry
The active vitamin D compound paricalcitol had no effect on left ventricular mass index (LVMI) or measures of diastolic dysfunction in patients with chronic kidney disease (CKD), according to the results of a multinational, double-blind, randomized, placebo-controlled trial. The fi ndings, from the Paricalcitol Capsule Benefits in Renal Failure-Induced Cardiac Morbidity (PRIMO) trial, were published in the Journal of the American Medical Association (JAMA 2012;307:674-684). The negative result surprised the PRIMO investigators. “Animal studies suggested paricalcitol would have a dramatic effect and improve cardiovascular health, but that did not translate to the human studies,” said lead author Ravi Thadhani, MD, MPH, Associate Professor of Medicine at Harvard Medical School, in an interview. “In the human studies, we found that there were fewer hospitalizations for cardiovascularrelated disease and lower levels of BNP [brain natriuretic peptide], which is a marker of cardiac stress, but we didn’t fi nd changes in the cardiac mass, and this was surprising,” Dr. Thadhani said. “This suggests that, if indeed this type of agent has a dramatic effect on the heart, it’s not because it reduces cardiac mass; it works through other mechanisms that may play a role in heart failure.” Paricalcitol is used to treat elevated parathyroid hormone levels in patients with CKD who are vitamin D defi cient. Data have suggested that the compound may also decrease cardiovascularrelated morbidity and mortality, In a Surprising Finding, Paricalcitol Fails to Improve Cardiac Measures
{"title":"In a Surprising Finding, Paricalcitol Fails to Improve Cardiac Measures","authors":"F. Lowry","doi":"10.1097/01.NEP.0000413832.96692.2A","DOIUrl":"https://doi.org/10.1097/01.NEP.0000413832.96692.2A","url":null,"abstract":"The active vitamin D compound paricalcitol had no effect on left ventricular mass index (LVMI) or measures of diastolic dysfunction in patients with chronic kidney disease (CKD), according to the results of a multinational, double-blind, randomized, placebo-controlled trial. The fi ndings, from the Paricalcitol Capsule Benefits in Renal Failure-Induced Cardiac Morbidity (PRIMO) trial, were published in the Journal of the American Medical Association (JAMA 2012;307:674-684). The negative result surprised the PRIMO investigators. “Animal studies suggested paricalcitol would have a dramatic effect and improve cardiovascular health, but that did not translate to the human studies,” said lead author Ravi Thadhani, MD, MPH, Associate Professor of Medicine at Harvard Medical School, in an interview. “In the human studies, we found that there were fewer hospitalizations for cardiovascularrelated disease and lower levels of BNP [brain natriuretic peptide], which is a marker of cardiac stress, but we didn’t fi nd changes in the cardiac mass, and this was surprising,” Dr. Thadhani said. “This suggests that, if indeed this type of agent has a dramatic effect on the heart, it’s not because it reduces cardiac mass; it works through other mechanisms that may play a role in heart failure.” Paricalcitol is used to treat elevated parathyroid hormone levels in patients with CKD who are vitamin D defi cient. Data have suggested that the compound may also decrease cardiovascularrelated morbidity and mortality, In a Surprising Finding, Paricalcitol Fails to Improve Cardiac Measures","PeriodicalId":380758,"journal":{"name":"Nephrology Times","volume":"341 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2012-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132168533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2012-03-01DOI: 10.1097/01.NEP.0000413833.96692.63
M. Hogan
{"title":"Experts Disagree with FDA Rejection of New Ezetimibe/Simvastatin Indication","authors":"M. Hogan","doi":"10.1097/01.NEP.0000413833.96692.63","DOIUrl":"https://doi.org/10.1097/01.NEP.0000413833.96692.63","url":null,"abstract":"","PeriodicalId":380758,"journal":{"name":"Nephrology Times","volume":"48 4 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2012-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133840546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：